Galectin Therapeutics reported $-9.17M in EBIT for its fiscal quarter ending in September of 2023.





Ebit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Galectin Therapeutics USD -9.17M 163K Sep/2023
Gilead Sciences USD 3.85B 1.17B Jun/2026
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD -707.47M 1.41B Sep/2026
Merck USD 7.33B 6.49B Sep/2026